Summary:
Pacific Sleep Medicine is conducting a Twelve Week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study of the Safety and Efficacy of JZP-110 [(r)-2-amino-3-phenylpropylcarbamate hydrochloride] in the Treatment of Excessive Sleepiness in Subjects with Narcolepsy, and Obstructive Sleep Apnea.
Qualified Participants Must:
• Be between 18 and 70 years of age
•
Have a diagnosis of Narcolepsy, or OSA
•
Sleep a total of at least 6 hours a night
•
Be willing and able to comply with the study design schedule and other requirements
•
Be willing and able to sign informed consent
Qualified Participants May Receive:
Reimbursement for study related visits.